Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2008 Sep 16;99(7):1056–1063. doi: 10.1038/sj.bjc.6604634

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2008 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Tumour protein expression levels of VEGF, VEGFR-1, and CYP1B1 after treatment with EGCG and tamoxifen. Mice were treated with vehicle (5 ml kg⁻¹), EGCG (25 mg kg⁻¹, i.p.), tamoxifen (75 μg kg⁻¹, p.o.), or EGCG+tamoxifen for 70 days. (A) Representative western blots of the various proteins from each individual mouse. (B) The results of scanning densitometry of western blots. For clarity, densitometry is shown only for proteins that were modulated by drug treatment. Bars represent the mean±s.e.m. from 10 mice per group. (C) Representative immunohistochemistry of CYP1B1 and VEGFR-1 from tumour sections of treated mice. ^*Significantly different from vehicle control (P<0.05). ^**Significantly different from vehicle and tamoxifen (P<0.01). ^***Significantly different from all other treatments (P<0001).